FlexFix, an early stage medical device company focused on commercializing its proprietary implantable ‘flexible-to-rigid’ technologies in the orthopedic and spine markets, has completed the acquisition of certain intellectual property assets from Novalign Orthopaedic.

The acquired assets include numerous US and international patent filings that will further strengthen the company’s patent portfolio.

NovaLign Orthopaedics, formerly known as OsteoLign, develops minimally invasive products for treating fractures of thigh, shin, calf, and various long bones in the human body.

It offers intramedullary fixation system, a system of implants and instruments for the treatment of long bone fractures, including the humerus, tibia, and femur; and extra-capsular intramedullary device that allows a surgeon to repair a long bone fracture without violating the nearby joint space.

FlexFix is developing products that will provide surgeons with the option to treat those same patients with a minimally invasive, percutaneous fixation technique, potentially reducing morbidity, reducing recovery time and improving function over current treatment options.